Company / Operating Cash Flow
Royalty Pharma plc Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$2.5B
FY2025
5-year range
$1.7B / $3.0B
FY2021-FY2025
Trend
-10.1%
vs FY2024
Sector context
#13 of 216
Health Care
What the data says
Among 216 Health Care companies, Royalty Pharma plc is in the top 6% for operating cash flow. Operating Cash Flow has fluctuated over the past 8 years, ranging from $1.6B in FY2020 to $3.0B in FY2023.
Based on SEC 10-K filings.
$2.5B in FY2025 with a 5-year CAGR of +9.0%. Top quartile in the Health Care sector.
Declined from $3.0B to $2.5B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +7.0%
- 5-Year CAGR
- +9.0%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 216This company $2.5B Sector average $659.0M
▼
+277.8% above sector average
Key checks
Key Insights
- 5-year CAGR of +9.0%, indicating consistent growth.
- In FY2025, operating cash flow decreased 10.1% year-over-year.
- Ranks #13 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5B | -10.1% |
| FY2024 | $2.8B | -7.3% |
| FY2023 | $3.0B | +46.8% |
| FY2022 | $2.0B | +22.0% |
| FY2021 | $1.7B | +3.0% |
| FY2020 | $1.6B | -2.9% |
| FY2019 | $1.7B | +3.0% |
| FY2018 | $1.6B | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026